Balkan Pharmaceuticals has become a nationally and internationally recognized name in the drug market. Recently, the brand has been awarded the NOTORIUM trophy as a recognized brand for the third consecutive year. Here are what actions have made them noted in the field for this year and what the company’s plans are for 2020.
“It is a very important award for our company. It means appreciation and recognition from our partners and from our patients – everyone who chooses Balkan Pharmaceuticals. We are the number 1 brand in the field of pharmaceuticals manufacturing, in Moldova!” declared Alina Doroschevici, quality assurance specialist.
In 2019 Balkan Pharmaceuticals has entered into several partnership agreements with international pharmaceutical companies, committing itself to produce medicines and food supplements for the CIS, EU, Middle East and Southeast Asia markets. This will stimulate exports of Made in Moldova drugs, contributing to a positive image of the country. Another direction of development is genetic engineering – several specialists from Balkan Pharmaceuticals have completed courses under the aegis of international bodies on the implementation of new methods of obtaining drugs. In 2020, the implementation of the technology transfer plan is due.
We will work more in the field of dietary supplements – Balkan Pharmaceuticals, together with international business partners; have developed a range of dietary supplements that they plan to launch in 2020. The new range includes products designed to achieve and maintain optimum body weight (body care, weight loss), for the beauty and health of the skin and hair, for maintaining a psycho-emotional balance, for enhancing sports performance, etc.
“Recently, Balkan Pharmaceuticals has initiated the construction of a new industrial complex for the production of antibiotics. The new complex is due to be completed by 2021. With its launch, Balkan Pharmaceuticals will produce and market antibiotics at cheaper prices than import ones, which will favor the choice of patients”, declared Alina Doroschevici, quality assurance specialist.
At the moment, the Republic of Moldova is dependent on the import of drugs in a proportion of about 90%, the share of domestic producers being up to 10%. “This endangers the national pharmaceutical safety: if importers give up supplementing the market with certain drugs, patients may be left without the main sources of treatment.
“The mission of Balkan Pharmaceuticals is to contribute to ensuring the pharmaceutical safety of the Republic of Moldova, by continuously expanding and diversifying the portfolio of medicines produced. If at the beginning of its activity, Balkan Pharmaceuticals produced only a few types of medicines, today we produce more than 300 drugs, from different pharmacy-therapeutic groups (for the cardiovascular, digestive, respiratory systems, analgesic, anti-inflammatory, antimycotic, antitumor drugs etc.), in different forms and doses (tablets, capsules, injectable solutions, etc.). At the same time, we are in a permanent dialogue with the medical institutions and with the relevant authorities, in order to produce and deliver medicines absolutely necessary for the normal activity of the national health care system”, Balkan Pharmaceuticals representatives reported.
